Blog
The case for patient-controlled rare disease data across science, policy, and the lived experience.
Featured
Vision
It is no longer good business to leave rare diseases behind
The math changed. The institutions that retool first capture leadership.
Read →This week
Regulatory
Our FDA Comment: AI-Enabled Optimization of Early-Phase Clinical Trials Pilot Program
Cureledger's May 27, 2026 comment to Docket FDA-2026-N-4390: rare disease as the pilot's most generalizable use case, within-person variability as the decision-quality threshold, privacy for cohorts under 100, and data custody that outlives the sponsor.
Read →Data Sovereignty
Preventing AI medicine's biggest trap for rare disease
Why AI drug discovery becomes extraction without ownership infrastructure.
Read →
Vision
The rare disease singularity
Four capabilities converged. Cures are reachable.
Read →Search articles
Browse by tag
Clear ×Read all14 of 109 · Tag: Ehlers-Danlos
- May 7, 2026The EDS diagnosis problem solves itself
- May 7, 2026The 14 EDS subtypes, in plain words
- May 7, 2026Vascular EDS, the dangerous subtype
- May 7, 2026Classical EDS, the original
- May 7, 2026Kyphoscoliotic EDS
- May 7, 2026Cardiac-valvular EDS
- May 7, 2026Dermatosparaxis EDS
- May 7, 2026The Beighton Score Problem
- May 7, 2026EDS and pregnancy
- May 7, 2026Lidocaine resistance and EDS
- May 7, 2026The Diagnostic Odyssey as Systems Failure
- May 7, 2026Three Specialists Who Don't Talk to Each Other
- Apr 28, 2026Serola SI belt, a daily-life spotlight
- Apr 28, 2026hEDS criteria 2017, for the newly diagnosed